Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|October 24, 2011
Jeffrey Barrett: AAPS 2011 Profile
Advertisement
Jeffrey Barrett
Jeffrey S. Barrett, PhD, is a Research Professor in the University of Pennsylvania School of Medicine and Director of the Laboratory for Applied PK/PD at the Children's Hospital of Philadelphia (CHOP). His research is focused on developing mathematical models to guide the design and analysis of both translational science experiments and clinical trials. These studies are pivotal to the development of new medicines and to improve our understanding of disease biology. Dr Barrett's group develops decision support tools that interface such models with hospital-based medical records systems to guide drug therapy in critically-ill children. Much of his effort has been focused in children with cancer where Dr Barrett works with colleagues at CHOP to a find cure for infant leukemia.
View Full Research
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5